Schwab Charles Investment Management Inc. lowered its stake in Orthofix International N.V. (NASDAQ:OFIX) by 10.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 116,394 shares of the medical device company’s stock after selling 13,666 shares during the period. Schwab Charles Investment Management Inc.’s holdings in Orthofix International were worth $5,500,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of OFIX. Dimensional Fund Advisors LP raised its holdings in shares of Orthofix International by 11.6% in the second quarter. Dimensional Fund Advisors LP now owns 870,120 shares of the medical device company’s stock worth $40,443,000 after buying an additional 90,349 shares during the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in shares of Orthofix International in the second quarter worth $3,774,000. TIAA CREF Investment Management LLC raised its holdings in shares of Orthofix International by 34.6% in the second quarter. TIAA CREF Investment Management LLC now owns 183,179 shares of the medical device company’s stock worth $8,514,000 after buying an additional 47,103 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of Orthofix International in the third quarter worth $2,121,000. Finally, Teachers Advisors LLC raised its holdings in shares of Orthofix International by 15.9% in the second quarter. Teachers Advisors LLC now owns 320,404 shares of the medical device company’s stock worth $14,892,000 after buying an additional 44,064 shares during the last quarter. 94.61% of the stock is owned by institutional investors and hedge funds.
In related news, CEO Brad Mason sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total transaction of $267,400.00. Following the completion of the transaction, the chief executive officer now owns 183,053 shares of the company’s stock, valued at $9,789,674.44. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Luke T. Faulstick sold 4,800 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $51.22, for a total transaction of $245,856.00. Following the transaction, the director now directly owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The disclosure for this sale can be found here. In the last three months, insiders have sold 15,347 shares of company stock valued at $802,144. 5.60% of the stock is currently owned by corporate insiders.
Orthofix International (NASDAQ:OFIX) last issued its earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.01. Orthofix International had a net margin of 0.33% and a return on equity of 10.26%. The firm had revenue of $105.30 million during the quarter, compared to analysts’ expectations of $100.67 million. During the same quarter last year, the company posted $0.36 earnings per share. The firm’s revenue was up 6.9% compared to the same quarter last year. analysts anticipate that Orthofix International N.V. will post 1.61 earnings per share for the current fiscal year.
OFIX has been the subject of a number of research analyst reports. Zacks Investment Research cut shares of Orthofix International from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 11th. BTIG Research set a $56.00 price target on shares of Orthofix International and gave the stock a “buy” rating in a report on Monday, October 30th. TheStreet cut shares of Orthofix International from a “b” rating to a “c+” rating in a report on Tuesday, October 31st. Finally, BidaskClub cut shares of Orthofix International from a “hold” rating to a “sell” rating in a report on Thursday, December 14th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Orthofix International presently has a consensus rating of “Buy” and a consensus price target of $54.42.
TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.com-unik.info/2018/01/09/orthofix-international-n-v-ofix-shares-sold-by-schwab-charles-investment-management-inc.html.
Orthofix International Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix International N.V. (NASDAQ:OFIX).
What are top analysts saying about Orthofix International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orthofix International and related companies.